Hepatic subcapsular steatosis as a complication associated with intraperitoneal insulin treatment in diabetic peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 25, Issue 6, 2005, Pages 596-600

  Torun, Dilek ^a   Oguzkurt, Levent ^a   Sezer, Siren ^a   Zumrutdal, Aysegul ^a   Singan, Metin ^a   Adam, Fatma Ulku ^a   Ozdemir, Fatma Nurhan ^a   Haberal, Mehmet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Diabetes mellitus; Fatty liver; Insulin; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; INSULIN; LIPID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIALYSATE; DISEASE DURATION; DRUG DOSE REGIMEN; FATTY LIVER; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN TREATMENT; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

EID: 30944467729     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500617     Document Type: Article

References (15)

1. Fernstrom A, Hylander B, Moritz A, Jacobsson H, Rossner S. Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18:166-71.
2. Wanless IR, Bargman JM, Oreopoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol 1989; 2:69-74.
3. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
4. Schade DS, Eaton RP, Friedman NM, Spencer WJ. Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia 1980; 19: 35-9.
5. Scarpioni L, Ballocchi S, Scarpioni R, Cristinelli L. Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Perit Dial Int 1996; 16(Suppl 1):S275-8.
6. Feriani M, Dell'Aquila R, La Greca G. The treatment of diabetic end-stage renal disease with peritoneal dialysis. Nephrol Dial Transplant 1998; 13(Suppl 8):53-6.
7. Bargman JM. The impact of intraperitoneal glucose and insulin on the liver. Perit Dial Int 1996; 16(Suppl 1): S211-14.
8. Katz J, McGarry JD. The glucose paradox. Is glucose a substrate for liver metabolism? J Clin Invest 1984; 74:1901-9.
9. Correa-Rotter R, Cueto-Manzano A. The problem of the high transporter: is survival decreased. Perit Dial Int 2001; 21(Suppl 3):S75-9.
10. Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L. Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients. Nephron 1986; 42:133-40.
11. Randazzo PA, Jarett L. Characterization of the growth of murine fibroblasts that express human insulin receptors. II. Interaction of insulin with other growth factors. Exp Cell Res 1990; 190:31-9.
12. Nevalainen PI, Kallio T, Lahtela JT, Mustonen J, Pasternack AI. High peritoneal permeability predisposes to hepatic steatosis in diabetic continuous ambulatory peritoneal dialysis patients receiving intraperitoneal insulin. Perit Dial Int 2000; 20:637-42.
13. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18:353-8.
14. Baron RL, Gore RM. Diffuse liver disease. In: Gore RM, Levine MS, eds. Textbook of Gastrointestinal Radiology. 2nd ed. Philadelphia: WB Saunders Company; 2000: 1591-4.
15. Halvorsen RA, Korobkin M, Ram PC, Thompson WM. CT appearance of focal fatty infiltration of the liver. AJR Am J Roentgenol 1982; 139:277-81.